Core Points - Theratechnologies Inc. held its annual meeting of shareholders in a virtual-only format and reported the voting results [1] - Shareholders elected candidates to the Board of Directors, appointed KPMG LLP as auditors, and approved a long-term incentive plan [2] Voting Results - Joseph Arena received 20,473,944 votes (84.03% for) with 3,890,222 abstentions (15.97%) [3] - Frank Holler received 19,089,786 votes (78.35% for) with 5,274,380 abstentions (21.65%) [3] - Paul Lévesque received 19,027,772 votes (78.10% for) with 5,336,394 abstentions (21.90%) [3] - Andrew Molson received 19,066,145 votes (78.25% for) with 5,298,021 abstentions (21.75%) [3] - Dawn Svoronos received 18,998,230 votes (77.98% for) with 5,365,936 abstentions (22.02%) [3] - Elina Tea received 19,163,502 votes (78.65% for) with 5,200,664 abstentions (21.35%) [3] - Dale Weil received 19,005,768 votes (78.01% for) with 5,358,398 abstentions (21.99%) [3] - Jordan Zwick received 19,618,725 votes (80.52% for) with 4,745,441 abstentions (19.48%) [3] Company Overview - Theratechnologies is a biopharmaceutical company focused on innovative therapies that aim to redefine standards of care [4]

Core Insights - Theratechnologies Inc. presented two significant studies at the 19th Annual American Conference for the Treatment of HIV, focusing on excess visceral abdominal fat (EVAF) in people with HIV (PWH) [1][2][3] VAMOS Analysis - The VAMOS study revealed that EVAF is linked to reduced muscle quality in aging PWH, with a prevalence of 58% among 170 participants [5] - Muscle quality declines with age (r= -0.465; p<0.0001) but is not significantly correlated with body mass index (BMI) (r= -0.118; p=0.124) [5] - Increased visceral fat correlates strongly with lower skeletal muscle quality (r= -0.445; p<0.0001), suggesting it may exacerbate age-related functional decline [5] Tesamorelin/GLP-1 RA Case Series - A case series demonstrated the effectiveness of combining tesamorelin and GLP-1 receptor agonists (RAs) in treating EVAF in PWH, with a mean waist circumference reduction of 1.3 inches [7] - After at least six months of combination therapy, patients experienced mean reductions in weight (-13 pounds), BMI (-2.2 kg/m²), and waist circumference (-3.4 inches), with six out of seven patients meeting their metabolic and body composition goals [7] - This is the first report of dual use of tesamorelin and GLP-1 RAs in PWH, highlighting their complementary mechanisms [7][8]

Core Insights - Theratechnologies (NASDAQ: THTX) shares are trading at approximately $2.52 as of April 18, 2025, despite an unsolicited proposal from Future Pak valuing the company between $3.51 and $4.50 per share [1] Company Summary - The current share price of Theratechnologies is significantly lower than the valuation proposed by Future Pak, indicating a potential investment opportunity [1]

Core Viewpoint - Theratechnologies Inc. is evaluating the potential sale of the company following a proposal from Future Pak, with a special committee overseeing the process [1][2] Group 1: Company Overview - Theratechnologies is a commercial-stage biopharmaceutical company focused on innovative therapies that aim to redefine standards of care [3] Group 2: Board and Committee Actions - The Board of Directors has authorized a special committee of independent directors to oversee the evaluation of the potential sale [1] - The special committee has engaged multiple advisors, including Barclays, Fasken, Raymond James, and Norton Rose Fulbright, to assist in the process [1] Group 3: Ongoing Operations - Despite ongoing discussions regarding the potential sale, the company reassures stakeholders that operations will continue as normal [2]

Core Viewpoint - Theratechnologies Inc. is currently in discussions regarding a potential acquisition by Future Pak, LLC, with a special committee formed to evaluate the proposals and ensure the best interests of the Company and its stakeholders are met [1][2]. Group 1: Acquisition Proposals - Future Pak has conducted extensive due diligence on Theratechnologies and negotiations for a definitive agreement are ongoing [1]. - A "go shop" provision is expected to be included in any definitive agreement, allowing Theratechnologies to engage with other potential acquirers after the agreement is signed [1]. - The Company received an unsolicited non-binding acquisition proposal from Future Pak in August 2024, which was rejected due to unattractive terms [6]. Group 2: Special Committee and Advisors - A special committee of independent directors has been established to review acquisition proposals and determine the best course of action [2]. - The special committee is being advised by Barclays Capital Inc. as a financial advisor and Fasken Martineau DuMoulin LLP as external legal counsel [2]. Group 3: Future Engagements - Future Pak's proposals were made without completing due diligence beyond publicly available information, and the Company has indicated that Future Pak will have future opportunities to engage [6]. - The Company does not intend to provide further updates on the acquisition discussions to allow the special committee to focus on its mandate [3].

Core Viewpoint - Theratechnologies Inc. is currently in discussions with Future Pak, LLC regarding a potential acquisition, with a special committee formed to evaluate the proposals and ensure the best interests of the Company and its stakeholders are prioritized [1][2]. Group 1: Acquisition Proposals - Future Pak has conducted extensive due diligence on Theratechnologies and negotiations for a definitive agreement are ongoing [1]. - A "go shop" provision is expected to be included in any definitive agreement, allowing Theratechnologies to engage with other potential acquirers after the agreement is signed [1]. - The Company received an unsolicited non-binding acquisition proposal from Future Pak in August 2024, which was rejected due to unattractive terms [6]. Group 2: Special Committee and Advisors - A special committee of independent directors has been established to review acquisition proposals and determine the best course of action for the Company [2]. - The special committee is being advised by Barclays Capital Inc. as a financial advisor and Fasken Martineau DuMoulin LLP as external legal counsel [2]. Group 3: Future Engagements - Future Pak's proposals were made without completing due diligence beyond publicly available information, and the Company has indicated that Future Pak will have future opportunities to engage with them [6]. - The Company does not intend to provide further updates on the acquisition discussions to allow the special committee to focus on its mandate [3].

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 reached $19 million, representing a 17% growth from the same period last year [10] - Adjusted EBITDA for Q1 2025 was $2.3 million, compared to an adjusted EBITDA loss of $247,000 in the same period last year [28] - The last 12 months adjusted EBITDA figure stands at $22.7 million on LTM sales of approximately $89 million, resulting in a margin of over 25% [28] Business Line Data and Key Metrics Changes - Net sales of EGRIFTA SV reached $13.9 million in Q1 2025, a 45% increase year-over-year from $9.6 million [30] - Trogarzo net sales in Q1 2025 amounted to $5.2 million, a decrease of 22% from $6.7 million in the same quarter last year [31] - Cost of goods sold decreased to $3.5 million from $5.3 million in the same quarter last year [32] Market Data and Key Metrics Changes - New enrollments for EGRIFTA SV were up 15% in Q1 2025 compared to the previous year, indicating a growing patient base [16] - The company experienced a temporary drug shortage that impacted sales, resulting in an estimated loss of $10 million in revenue [30] Company Strategy and Development Direction - The company is focusing on increasing the bottom line and is committed to prudent spending while expanding its portfolio through acquisitions and in-licensing of late-stage products [22][23] - The strategic priority is to find products that can drive meaningful synergies with the current infrastructure [23] - The company is preparing for the launch of olezarsen and donidalorsen in Canada later this year [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of the EGRIFTA franchise, citing increased recognition of excess visceral abdominal fat (EVAF) as a serious health condition [11][56] - The company anticipates continued growth in enrollments and patient numbers, indicating robust demand for its products [58] - Management is closely monitoring the impact of tariffs but does not foresee significant implications for its products [26][70] Other Important Information - The company has mapped out its supply chains in light of potential tariffs and does not expect significant impacts on its operations [26] - The transition from EGRIFTA SV to EGRIFTA WR is planned for early 2026, with a focus on ensuring a seamless process [52] Q&A Session Summary Question: Are you looking for new products in the same therapeutic areas? - The company aims to focus on late-stage products with a high chance of success and synergies with existing infrastructure [41][42] Question: How do you plan to facilitate the transition from EGRIFTA SV to EGRIFTA WR? - The transition will be carefully orchestrated to ensure payers are ready to reimburse the new product, with a planned six-month transition period [52] Question: Why is it taking so long for Trogarzo sales to stabilize? - The company is experiencing a loss of existing patients due to previous higher enrollments, but new enrollments are showing positive growth [64] Question: Do you foresee any tariff impacts on Trogarzo or Ionis products? - The company does not anticipate issues with Trogarzo due to transfer pricing and does not see risks for Ionis products manufactured in Europe [67][68] Question: What is the status of the NASH program? - The company is opportunistic regarding potential partnerships in the NASH space but is not currently focused on this area [72]

Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three-month periods ended February 28, 2025 and February 29, 2024 (Unaudited) T H E RAT E C H N O L O G I E S I N C . Ta b l e o f C o n t e n t s ( I n t h o u s a n d s o f U n i t e d S t a t e s d o l l a r s ) ( U n a u d i t e d ) P a g e I n t e r i m C o n s o l i d a t e d S t a t e m e n t s o f F i n a n c i a l P o s i t i o n 1 I n t e r i m C o n s o l i d a t e d S t a t e m e ...

Core Insights - Theratechnologies reported a total revenue of $19 million for Q1 2025, reflecting a year-over-year growth of 17% [2][15][30] - The company achieved a net profit of $117,000, a significant improvement from a net loss of $4.48 million in Q1 2024 [30][34] - EGRIFTA SV® net sales increased by 44.8% to $13.88 million, while Trogarzo® sales decreased by 22.4% to $5.17 million [2][18] Financial Performance - Total revenue for Q1 2025 was $19,047,000 compared to $16,247,000 in Q1 2024, marking a 17.2% increase [15] - EGRIFTA SV® sales reached $13,880,000, up from $9,586,000 in the previous year, driven by higher unit sales and pricing [16] - Trogarzo® sales fell to $5,167,000 from $6,661,000, primarily due to lower unit sales [18] Recent Developments - The FDA approved EGRIFTA WR™ on March 25, 2025, which is expected to enhance the company's product offerings for treating excess visceral abdominal fat in adults with HIV [3][37] - The company resumed distribution of EGRIFTA SV® on February 14, 2025, following a temporary supply disruption due to a manufacturing shutdown [9][36] - The approval of the Prior Approval Supplement (PAS) for EGRIFTA SV® on April 7, 2025, allows for regular distribution without further FDA authorization [10][37] Research and Development - R&D expenses decreased by 21.2% to $2,969,000 in Q1 2025, attributed to lower spending on life-cycle management and oncology programs [22] - The company presented data at CROI highlighting the limitations of BMI in assessing cardiovascular risk in people with HIV [11] Guidance and Outlook - The company estimates FY2025 revenue to be between $80 million and $83 million, considering the impact of the supply disruption and the new product launch [13] - Adjusted EBITDA for Q1 2025 was $2,321,000, a significant improvement from a loss of $247,000 in the same period last year [28]

Core Insights - The FDA has approved Theratechnologies' Prior Approval Supplement (PAS) for EGRIFTA SV®, allowing unrestricted distribution and removing previous supply uncertainties [1][2][3] - The new formulation, EGRIFTA WR™, has also been approved by the FDA and is set to replace EGRIFTA SV® in the U.S. market [2][3] Company Overview - Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on innovative therapies, particularly for HIV-related conditions [1][8] - The company aims to improve patient experience with the new EGRIFTA WR™ formulation, which is designed to be more convenient [3] Product Information - EGRIFTA SV® (tesamorelin for injection) is the only FDA-approved treatment for reducing excess abdominal fat in adults with HIV and lipodystrophy [1][3] - Tesamorelin acts as a growth hormone-releasing factor (GHRF) analog, stimulating the production and release of endogenous growth hormone [3] Regulatory Developments - The approval of the PAS eliminates the need for discretionary product release, enabling the company to resume regular distribution of EGRIFTA SV® [2] - The transition to EGRIFTA WR™ is anticipated to enhance patient compliance and overall treatment experience [3]